FRA, 6Z4 End of Day and Historical Stock Data []

The worlds #1 website for end of day & historical stock data

wide range of exchanges, data formats, tools and services

APINEW HISTORICAL DATA SYMBOL LISTS MEMBERSHIP REGISTER LOG IN

FRA, 6Z4: Crinetics Pharmaceuticals Inc

03 Sep 2025

LAST: 28.40	CHANGE: 2.00	OPEN: 28.40	HIGH: 28.40	ASK: 0.00	VOLUME: 20
LAST: 28.40	CHG(%): 7.58	PREV: 26.40	LOW: 28.40	BID: 0.00

CHART

Period:

RECENT END OF DAY PRICES

Date	Open	High	Low	Close	Volume
03 Sep 25	28.40	28.40	28.40	28.40	20
02 Sep 25	26.40	26.40	26.40	26.40	20
01 Sep 25	26.40	26.40	26.40	26.40	20
29 Aug 25	26.20	26.20	26.20	26.20	20
28 Aug 25	26.00	26.00	26.00	26.00	20
27 Aug 25	26.60	26.60	26.60	26.60	20
26 Aug 25	25.80	25.80	25.80	25.80	20
25 Aug 25	26.20	26.20	26.20	26.20	20
22 Aug 25	25.20	25.20	25.20	25.20	20
21 Aug 25	24.80	24.80	24.80	24.80	20

COMPANY PROFILE

Name:	Crinetics Pharmaceuticals Inc
About:	Crinetics Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company's lead product candidate is Paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist, which is in a Phase 3 clinical trial for the treatment of acromegaly and carcinoid syndrome associated with neuroendocrine tumors. It is also developing Atumelnant, an investigational oral nonpeptide product candidate to antagonize the adrenocorticotrophic hormone (ACTH) receptor that has completed a Phase 1 study for the treatment of diseases caused by excess ACTH, including congenital adrenal hyperplasia and cushing's disease; and CRN09682, a nonpeptide drug conjugate for SST2 positive solid tumors. In addition, the company is developing antagonists of the parathyroid hormone (PTH) receptor for the treatment of primary hyperparathyroidism and humoral hypercalcemia of malignancy, and other diseases of excess PTH; thyroid-stimulating hormone receptor antagonists for the treatment of graves' disease and thyroid eye disease; SST3 Agonist program for the treatment for autosomal dominant polycystic kidney disease; and Radionetics for multiple solid-tumors, as well as Oral GLP-1 and Oral GIP nonpeptides for the treatment of obesity. The company has an agreement with Sanwa Kagaku Kenkyusho Co., Ltd to develop and commercialize Paltusotine in Japan, and Cellular Longevity, Inc. to develop and commercialize CRN01941, a somatostatin receptor type 2 agonist. Crinetics Pharmaceuticals, Inc. was incorporated in 2008 and is headquartered in San Diego, California.
Sector:	Healthcare
Industry:	Biotechnology
Address:	6055 Lusk Boulevard, San Diego, CA, United States, 92121
Website:	https://www.crinetics.com
ISIN:	US22663K1079
LEI:	549300Q1CNFXK5P31D28

SYMBOL HISTORY

Purchase End of Day History
for this symbol from Jan 01, 0001

Add to Watchlist

DOWNLOAD DATA

Download stock quote history quickly and easily in a variety of formats to suit your needs.

Exchange:

Format:

Period:

Zip file

Symbol:

Start Date:

End Date:

TECHNICAL INDICATORS

MA5:	26.68
MA10:	26.20
MA20:	25.41
MA50:	25.67
MA100:	26.49
MA200:	32.98
STO9:	100.00
STO14:	100.00
RSI14:	65.22
MTM14:	3.60
ROC14:	0.15
ATR:	0.66
Week High:	28.40
Week Low:	26.00
Month High:	28.40
Month Low:	23.00
Year High:	56.76
Year Low:	22.35
Volatility:	31.02